ISB News

The Other Malaria: Finding New Targets for a Vaccine Against Plasmodium vivax

Warhol style Plasmodium

A new report in PLOS Neglected Tropical Diseases describes the results of an international collaboration led by researchers at ISB and Seattle’s Center for Infectious Disease Research (CIDResearch). We used mass spectrometry-based proteomics to identify nearly 2,000 proteins present in Plasmodium vivax parasites, one of the Plasmodium species that cause the disease malaria in humans. The work was done on parasites dissected from mosquito salivary glands, parasites that were in the form that is transmitted from mosquitoes to humans. Because parasite proteins can potentially be recognized by the body’s immune system, the proteins we have identified are promising targets for new vaccines against malaria.

Read More

Recent Articles

  • Dr. Sean Gibbons Promoted to Associate Professor

    Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…

  • AmeriCorps Member Sara Calder Joins ISB as Systems Health and STEM Coordinator

    Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.

  • In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

    Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.